🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GW642444 25

Found 26 matching trials

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

Study to Assess GW642444 in Asthma Patients

PHASE2

This is a study of GW642444M, a long-acting beta 2 specific agonist. This s...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-08

Trial ID

NCT00381667

Treatments Being Tested

GW642444M GW642444H placebo

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01328444

Treatments Being Tested

GSK 573719 +GW642444 125/25 GSK573719 + GW642444 62.5/25 GSK 573719 125 GSK 573719 62.5 GW642444 25 Plb

Phase I Study of GW642444M in Healthy Japanese Male Subjects

PHASE1

This is a randomized, double blind, placebo controlled, parallel-group, 7 d...

Status

Completed

Location

GSK Investigational Site

Start Date

2008-09-20

Trial ID

NCT00964249

Treatments Being Tested

GW642444 Placebo

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

PHASE3

The goal of asthma treatment is to achieve and maintain asthma control and ...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-10-20

Trial ID

NCT03248128

Treatments Being Tested

FF/VI via ELLIPTA DPI FF via ELLIPTA DPI

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-16

Trial ID

NCT01323660

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GSK573719 125 GSK573719 62.5 GW642444 25 placebo

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

PHASE3

This is a Phase III multicenter, randomized, double-blind, double-dummy, pa...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01316900

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GW642444 tiotropium bromide

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This is a multicenter, randomized, double-blind, double-dummy, parallel gro...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-04-04

Trial ID

NCT01822899

Treatments Being Tested

Umeclidinium bromide/Vilanterol Placebo ACCUHALER/DISKUS Fluticasone propionate/Salmeterol Placebo NDPI

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this 52-week study is to evaluate the long-term safety (in t...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-01-01

Trial ID

NCT01316887

Treatments Being Tested

125/25 mcg once-daily GSK573719/GW642444 125mcg once-daily GSK573719 Placebo once-daily

A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients

PHASE1

This study will involve the use of a new medicine called GW642444 being dev...

Status

Completed

Location

GSK Investigational Site

Start Date

2008-04-27

Trial ID

NCT00702910

Treatments Being Tested

Placebo GW642444 Magnesium Stearate

Previous Next